Business Context and Reporting Period
This Form 10-Q covers Gilead Sciences, Inc. for the three-month period ended March 31, 1996. Gilead is an early-stage biopharmaceutical company that has not yet generated revenue from product sales. Since its inception in 1987, the company has devoted resources to research and development (R&D) and has been unprofitable, with an accumulated deficit of approximately $123.6 million as of March 31, 1996.
Key Financial Metrics
| Metric | Q1 1996 | Q1 1995 |
|---|---|---|
| Total Revenues | $0.8 million | $0.9 million |
| Net Loss | $(10.8) million | $(8.9) million |
| Net Loss Per Share | $(0.42) | $(0.46) |
| Research & Development Expenses | $9.3 million | $8.1 million |
| Selling, General & Administrative Expenses | $4.8 million | $2.8 million |
| Net Interest Income | $2.6 million | $1.0 million |
| Cash and Cash Equivalents (End of Period) | $49.4 million | $30.4 million |
| Short-term Investments (End of Period) | $254.4 million | N/A |
| Total Liquidity (Cash + Investments) | $303.8 million | $30.4 million |
| Net Cash Used in Operating Activities | $(7.5) million | $(7.5) million |
| Net Cash Provided by Financing Activities | $156.4 million | $(0.6) million |
Material Changes vs. Prior Period
- Liquidity Surge: Total liquidity increased from approximately $30.4 million in Q1 1995 to $303.8 million in Q1 1996. This was driven by a public offering of common stock in February 1996, which generated $155.6 million in net proceeds.
- Expense Growth: R&D expenses rose 16% to $9.3 million due to increased staffing and clinical trial costs. Selling, general, and administrative (SG&A) expenses surged 75% to $4.8 million to support the establishment of marketing and sales capabilities.
- Interest Income: Net interest income increased 153% to $2.6 million, reflecting higher average cash and investment balances resulting from recent capital raises.
- Revenue Decline: Total revenues decreased slightly to $0.8 million from $0.9 million, primarily derived from collaborative research agreements.
Outlook, Risks, and Management Commentary
Collaborative Agreements: In March 1996, Gilead entered a new five-year collaborative research agreement with Glaxo Wellcome Inc. regarding "code blocker" technology. Glaxo will fund Gilead's research in this field, and Gilead received $3.0 million in March 1996 for the first year of the agreement.
Future Outlook: Management expects substantial losses to continue for the next several years due to ongoing R&D, clinical trials, and the build-out of commercialization infrastructure. The company anticipates significant growth in both R&D and SG&A expenses for the remainder of 1996.
Risks and Contingencies:
- Product Development: There is no assurance that product candidates will be effective, receive regulatory approval, or be commercially viable.
- Capital Requirements: While current resources are deemed adequate for the foreseeable future, additional equity or debt financing may be required. There is no assurance such funds will be available on favorable terms.
- Market Risks: The company faces intense competition, regulatory hurdles, and uncertainties regarding market acceptance of products like VISTIDE (cidofovir injection).
Investor Verification Checklist
- Verify the status and progress of clinical trials for product candidates, particularly VISTIDE.
- Monitor the terms and potential termination clauses of the new Glaxo Wellcome collaboration agreement.
- Track the rate of cash burn relative to the $303.8 million liquidity position to assess runway duration.
- Confirm the timeline for the establishment of sales and marketing capabilities and associated cost increases.
- Review the status of the proposed amendment to increase authorized common stock from 35 million to 60 million shares.